Pisces VII: Discovery of a possible satellite of Messier 33 in the DESI Legacy Imaging Surveys

We report deep imaging observations with DOLoRes@TNG of an ultra-faint dwarf satellite candidate of the Triangulum galaxy (M33) found by visual inspection of the public imaging data release of the DESI Legacy Imaging Surveys. Pisces VII/Triangulum (Tri) III is found at a projected distance of 72 kpc from M33, and using the tip of the red giant branch method we estimate a distance of D=1.0 +0.3,-0.2 Mpc, meaning the galaxy could either be an isolated ultra-faint or the second known satellite of M33. We estimate an absolute magnitude of M_V=-6.1+/-0.2 if Pisces VII/Tri II is at the distance of M33, or as bright as M_V=-6.8+/-0.2 if the galaxy is isolated. At the isolated distance, it has a physical half-light radius of r_h=131+/-61 pc consistent with similarly faint galaxies around the Milky Way. As the tip of the red giant branch is sparsely populated, constraining a precision distance is not possible, but if Pisces VII/Tri III can be confirmed as a true satellite of M33 it is a significant finding. With only one potential satellite detected around M33 previously (Andromeda XXII/Tri I), it lacks a significant satellite population in stark contrast to the similarly massive Large Magellanic Cloud. The detection of more satellites in the outskirts of M33 could help to better illuminate if this discrepancy between expectation and observations is due to a poor understanding of the galaxy formation process, or if it is due to the low luminosity and surface brightness of the M33 satellite population which has thus far fallen below the detection limits of previous surveys. If it is truly isolated, it would be the faintest known field dwarf detected to date.Comment: 10 pages, 9 figures, 2 tables, accepted for publication in MNRAS. This final version includes a moderate revision after the referee's comments and a correct titl

Pegasus V -- a newly discovered ultra-faint dwarf galaxy on the outskirts of Andromeda

We report the discovery of an ultra-faint dwarf in the constellation of Pegasus. Pegasus~V (Peg~V) was initially identified in the public imaging data release of the DESI Legacy Imaging Surveys and confirmed with deep imaging from Gemini/GMOS-N. The colour-magnitude diagram shows a sparse red giant branch (RGB) population and a strong over-density of blue horizontal branch stars. We measure a distance to Peg~V of $D=692^{+33}_{-31}$~kpc, making it a distant satellite of Andromeda with $M_V=-6.3\pm0.2$ and a half-light radius of $r_{\rm half}=89\pm41$~pc. It is located $\sim260$~kpc from Andromeda in the outskirts of its halo. The RGB is well-fit by a metal-poor isochrone with [Fe/H]$=-3.2$, suggesting it is very metal poor. This, combined with its blue horizontal branch could imply that it is a reionisation fossil. This is the first detection of an ultra-faint dwarf outside the deep Pan-Andromeda Archaeological Survey area, and points to a rich, faint satellite population in the outskirts of our nearest neighbour.Comment: Submitted to MNRAS Letters. 6 pages, 4 figures. Comments welcom

Once-weekly semaglutide use in patients with type 2 diabetes: Real-world data from the SURE Italy observational study

Aims: SURE Italy, a multicentre, prospective, open-label, observational, real-world study, investigated once-weekly semaglutide in patients with type 2 diabetes (T2D) in routine clinical practice. Materials and methods: Adults with T2D and ≥1 documented glycated haemoglobin (HbA1c) level within 12 weeks of semaglutide initiation were enrolled. The primary endpoint was change in HbA1c from baseline to end of study (EOS; ~30 weeks). Other endpoints included changes in body weight, waist circumference and patient-reported outcomes, and the proportion of patients achieving HbA1c <7.0% or <6.5%, weight loss ≥5% and a post-hoc composite endpoint (HbA1c reduction of ≥1%-point and weight loss ≥5%). These endpoints were reported for patients on semaglutide at EOS [effectiveness analysis set (EAS)]. Safety data were reported in the full analysis set. Results: Of 579 patients who initiated semaglutide (full analysis set), 491 completed the study on treatment (EAS). Mean baseline HbA1c was 8.0%, and 20.7% (120 of 579) of patients had HbA1c <7.0%. Mean semaglutide dose at EOS was 0.66 ± 0.28 mg. In the EAS, mean HbA1c and body weight decreased by 1.1%-point (95% confidence interval 1.20, 1.05; P < .0001) and 4.2 kg (95% confidence interval 4.63, 3.67; P < .0001), respectively. At EOS, 61.7% and 40.8% of patients achieved HbA1c <7.0% and <6.5%, respectively, 40.5% achieved weight loss ≥5% and 25.3% achieved the post-hoc composite endpoint. Patient-reported outcomes improved from baseline to EOS. No new safety concerns were identified. Conclusions: In routine clinical practice in Italy, patients with T2D treated with once-weekly semaglutide for 30 weeks achieved clinically significant improvements in HbA1c, body weight and other outcomes

Postoperative continuous positive airway pressure to prevent pneumonia, re-intubation, and death after major abdominal surgery (PRISM): a multicentre, open-label, randomised, phase 3 trial

Background: Respiratory complications are an important cause of postoperative morbidity. We aimed to investigate whether continuous positive airway pressure (CPAP) administered immediately after major abdominal surgery could prevent postoperative morbidity. Methods: PRISM was an open-label, randomised, phase 3 trial done at 70 hospitals across six countries. Patients aged 50 years or older who were undergoing elective major open abdominal surgery were randomly assigned (1:1) to receive CPAP within 4 h of the end of surgery or usual postoperative care. Patients were randomly assigned using a computer-generated minimisation algorithm with inbuilt concealment. The primary outcome was a composite of pneumonia, endotracheal re-intubation, or death within 30 days after randomisation, assessed in the intention-to-treat population. Safety was assessed in all patients who received CPAP. The trial is registered with the ISRCTN registry, ISRCTN56012545. Findings: Between Feb 8, 2016, and Nov 11, 2019, 4806 patients were randomly assigned (2405 to the CPAP group and 2401 to the usual care group), of whom 4793 were included in the primary analysis (2396 in the CPAP group and 2397 in the usual care group). 195 (8\ub71%) of 2396 patients in the CPAP group and 197 (8\ub72%) of 2397 patients in the usual care group met the composite primary outcome (adjusted odds ratio 1\ub701 [95% CI 0\ub781-1\ub724]; p=0\ub795). 200 (8\ub79%) of 2241 patients in the CPAP group had adverse events. The most common adverse events were claustrophobia (78 [3\ub75%] of 2241 patients), oronasal dryness (43 [1\ub79%]), excessive air leak (36 [1\ub76%]), vomiting (26 [1\ub72%]), and pain (24 [1\ub71%]). There were two serious adverse events: one patient had significant hearing loss and one patient had obstruction of their venous catheter caused by a CPAP hood, which resulted in transient haemodynamic instability. Interpretation: In this large clinical effectiveness trial, CPAP did not reduce the incidence of pneumonia, endotracheal re-intubation, or death after major abdominal surgery. Although CPAP has an important role in the treatment of respiratory failure after surgery, routine use of prophylactic post-operative CPAP is not recommended